La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Gr. Sarantis Bilan de santé

Santé financière contrôle des critères 6/6

Gr. Sarantis possède un total de capitaux propres de €353.6M et une dette totale de €70.3M, ce qui porte son ratio d'endettement à 19.9%. Son actif total et son passif total sont €553.5M et de €199.9M. L'EBIT de Gr. Sarantis est €47.1M ce qui fait que son ratio de couverture des intérêts 65.7. Elle dispose de liquidités et de placements à court terme de €114.0M.

Informations clés

19.9%

Ratio d'endettement

€70.35m

Dette

Ratio de couverture des intérêts	65.7x
Argent liquide	€113.96m
Fonds propres	€353.64m
Total du passif	€199.90m
Total des actifs	€553.54m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Kyriakos Sarantis Is The Vice Chairman & CEO of Gr. Sarantis S.A. (ATH:SAR) And Just Spent €118k On Shares

Feb 12

Is Gr. Sarantis S.A. (ATH:SAR) A Great Dividend Stock?

Jan 28

Will The ROCE Trend At Gr. Sarantis (ATH:SAR) Continue?

Jan 10

Who Has Been Selling Gr. Sarantis S.A. (ATH:SAR) Shares?

Dec 17

What Does Gr. Sarantis S.A.'s (ATH:SAR) Share Price Indicate?

Dec 04

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de SAR ( €319.3M ) dépassent ses passifs à court terme ( €109.0M ).

Passif à long terme: Les actifs à court terme de SAR ( €319.3M ) dépassent ses passifs à long terme ( €90.9M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: SAR dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de SAR a été réduit de 20.4% à 19.9% au cours des 5 dernières années.

Couverture de la dette: La dette de SAR est bien couverte par le flux de trésorerie opérationnel ( 84.3% ).

Couverture des intérêts: Les paiements d'intérêts de SAR sur sa dette sont bien couverts par l'EBIT ( 65.7 x couverture).

Gr. Sarantis Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

Executive Chairman recently bought €110k worth of stock

Price target increased by 14% to €13.93

Dividend increased to €0.22

Now 21% undervalued

New minor risk - Share price stability

Gr. Sarantis S.A. to Report First Half, 2024 Results on Sep 03, 2024

Price target increased by 9.0% to €9.48

Investor sentiment improves as stock rises 19%

Now 24% overvalued after recent price rise

Full year 2023 earnings released: EPS: €0.59 (vs €0.39 in FY 2022)

Gr. Sarantis S.A. to Report Fiscal Year 2023 Results on Mar 11, 2024

Price target increased by 10% to €8.50

Gr. Sarantis S.A., Annual General Meeting, Dec 20, 2023

Gr. Sarantis S.A. to Report Nine Months, 2023 Results on Nov 07, 2023

New major risk - Revenue and earnings growth

Price target increased by 10% to €7.98

First half 2023 earnings released: EPS: €0.29 (vs €0.17 in 1H 2022)

Gr. Sarantis S.A. to Report First Half, 2023 Results on Sep 11, 2023

New minor risk - Shareholder dilution

Full year 2022 earnings released

Price target decreased to €7.60

Less than half of directors are independent

Price target decreased to €7.60

Price target decreased to €7.78

First half 2022 earnings released: EPS: €0 (vs €0.29 in 1H 2021)

Gr. Sarantis S.A. to Report First Half, 2022 Results on Sep 08, 2022

An unknown buyer agreed to acquire 49% stake in ELCA Cosmetics Limited for €55.2 million.

Price target decreased to €8.48

Full year 2021 earnings: EPS misses analyst expectations

Less than half of directors are independent

Gr. Sarantis S.A., Annual General Meeting, May 24, 2022

Gr. Sarantis S.A. to Report Fiscal Year 2021 Results on Apr 29, 2022

CEO & Director recently sold €2.0m worth of stock

Capital Allocation Trends At Gr. Sarantis (ATH:SAR) Aren't Ideal

Investor sentiment deteriorated over the past week

Vice Chairman & CEO recently bought €86k worth of stock

Gr. Sarantis S.A. (ATSE:SAR) announces an Equity Buyback for 4,222,844 shares, representing 6.04% for €63.34 million.

Vice Chairman & CEO recently bought €119k worth of stock

Vice Chairman & CEO recently bought €248k worth of stock

First half 2021 earnings released: EPS €0.29 (vs €0.23 in 1H 2020)

Vice Chairman & CEO recently bought €61k worth of stock

Vice Chairman & CEO recently bought €90k worth of stock

Vice Chairman & CEO recently bought €915k worth of stock

Vice Chairman & CEO recently bought €69k worth of stock

Vice Chairman & CEO recently bought €217k worth of stock

Robust Earnings May Not Tell The Whole Story For Gr. Sarantis (ATH:SAR)

Full year 2020 earnings released: EPS €0.58 (vs €0.57 in FY 2019)

At €8.66, Is It Time To Put Gr. Sarantis S.A. (ATH:SAR) On Your Watch List?

New 90-day low: €8.75

Gr. Sarantis S.A. to Report Fiscal Year 2020 Results on Apr 08, 2021

Vice Chairman & CEO recently bought €96k worth of stock

I Built A List Of Growing Companies And Gr. Sarantis (ATH:SAR) Made The Cut

Kyriakos Sarantis Is The Vice Chairman & CEO of Gr. Sarantis S.A. (ATH:SAR) And Just Spent €118k On Shares

Vice Chairman & CEO recently bought €118k worth of stock

Is Gr. Sarantis S.A. (ATH:SAR) A Great Dividend Stock?

Will The ROCE Trend At Gr. Sarantis (ATH:SAR) Continue?

Who Has Been Selling Gr. Sarantis S.A. (ATH:SAR) Shares?

Vice Chairman & CEO recently bought €51k worth of stock

What Does Gr. Sarantis S.A.'s (ATH:SAR) Share Price Indicate?

Mehmet Yigit Sardan will acquire 15% interest in Sarantis Anadol from Sarantis.

Gr. Sarantis S.A. Not to Provide Financial Guidance for the Fiscal Year of 2020

First half earnings released

Gr. Sarantis S.A. to Report First Half, 2020 Results on Sep 02, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines